COMMERCIALIZING WORLD-CLASS CANCER INNOVATION

Seeding and scaling Ontario’s premiere entrepreneurial ventures for patients and the economy.

ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario

OUR IMPACT

Increasing the value of Ontario’s best oncology innovations and attracting investment from the private sector

invested

additional financing attracted

Ontario start-ups created

first-in-human studies

PORTFOLIO

Our investments are at the forefront of Ontario’s biotech ecosystem.

FIND OUT MORE

FUNDS

Our investments bridge the life sciences seed funding gap.

FIND OUT MORE

KEY SUCCESSES

Our investments have resulted in significant partnerships, clinical trials, job creation and leveraged financing for the province.

RECENT NEWS

Keep up to date on our investments and business developments in recent news stories and summaries.

  • Idea to Investment Podcast: How FACIT’s support propels early cancer innovations

    January 17, 2025 – FACIT’s David Koehler, Director of Fund Operations, appeared on TechAlliance’s Idea to Investment podcast along with Saumik Biswas, President, CEO and Founder of Tenomix Inc. based in London, Ontario. Tenomix’s advancements exemplifies how FACIT’s continuum of commercialization programs can strategically capitalize on homegrown talent and innovations to spur promising start-ups to…

    Read More

  • Esphera SynBio closes seed financing round to advance their lead designer cancer vaccine

    January 7, 2025 – FACIT congratulates portfolio company, Esphera SynBio (“Esphera”), on successfully securing seed financing and strategic partners to continue developing bespoke cancer immunotherapies using their proprietary engineered exosome-based platform for improved vaccine efficacy. Read More from Esphera SynBio closes seed financing round to advance their lead designer cancer vaccine

    Read More

  • Pitch Your Cancer Innovation at Falcons’ Fortunes 2025

    December 12, 2024 – Call for entrepreneurs and scientists to pitch your Ontario-made cancer innovation for a chance to win the $100,000 award. Falcons’ Fortunes is FACIT’s premier event to celebrate and grow the entrepreneurial spirit within the cancer research community. Apply by January 17, 2025. Read More from Pitch Your Cancer Innovation at Falcons’…

    Read More

  • FACIT investment in cTRL Therapeutics focuses cell therapy R&D on Ontario for patients with cancer

    October 10, 2024 – cTRL Therapeutics announced it is strengthening its research and development operations in Canada. Following an investment by FACIT, the company will establish a state-of-the-art laboratory and leverage Ontario’s world-leading cancer research network to accelerate advancement of its cancer therapeutics pipeline to benefit patients sooner. Read More from FACIT investment in cTRL…

    Read More

We were established by the Ontario Institute for Cancer Research (OICR) to support commercialization, technology transfer, and development activities. OICR conducts and enables world-class cancer research, filling a critical role as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together with OICR, we drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives. 

FACIT is funded in part by the Government of Ontario through OICR